《NEJM,6月29日,Multisystem Inflammatory Syndrome in U.S. Children and Adolescents》

  • 来源专题:COVID-19科研动态监测
  • 编译者: zhangmin
  • 发布时间:2020-06-30
  • Multisystem Inflammatory Syndrome in U.S. Children and Adolescents

    List of authors.

    Leora R. Feldstein, Ph.D., Erica B. Rose, Ph.D., Steven M. Horwitz, M.D., Jennifer P. Collins, M.D., Margaret M. Newhams, M.P.H., Mary Beth F. Son, M.D., Jane W. Newburger, M.D., M.P.H., Lawrence C. Kleinman, M.D., M.P.H., Sabrina M. Heidemann, M.D., Amarilis A. Martin, M.D., Aalok R. Singh, M.D., Simon Li, M.D., M.P.H., et al., for the Overcoming COVID-19 Investigators, and the CDC COVID-19 Response Team*

    Abstract

    BACKGROUND

    Understanding the epidemiology and clinical course of multisystem inflammatory syndrome in children (MIS-C) and its temporal association with coronavirus disease 2019 (Covid-19) is important, given the clinical and public health implications of the syndrome.

    METHODS

    We conducted targeted surveillance for MIS-C from March 15 to May 20, 2020, in pediatric health centers across the United States. The case definition included six criteria: serious illness leading to hospitalization, an age of less than 21 years, fever that lasted for at least 24 hours, laboratory evidence of inflammation, multisystem organ involvement, and evidence of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) based on reverse-transcriptase polymerase chain reaction (RT-PCR), antibody testing, or exposure to persons with Covid-19 in the past month. Clinicians abstracted the data onto standardized forms.

  • 原文来源:https://www.nejm.org/doi/full/10.1056/NEJMoa2021680
相关报告
  • 《NEJM,6月29日,Multisystem Inflammatory Syndrome in Children in New York State》

    • 来源专题:COVID-19科研动态监测
    • 编译者:zhangmin
    • 发布时间:2020-06-30
    • Multisystem Inflammatory Syndrome in Children in New York State List of authors. Elizabeth M. Dufort, M.D., Emilia H. Koumans, M.D., M.P.H., Eric J. Chow, M.D., M.P.H., Elizabeth M. Rosenthal, M.P.H., Alison Muse, M.P.H., Jemma Rowlands, M.P.H., Meredith A. Barranco, M.P.H., Angela M. Maxted, D.V.M., Ph.D., Eli S. Rosenberg, Ph.D., Delia Easton, Ph.D., Tomoko Udo, Ph.D., Jessica Kumar, D.O., et al., for the New York State and Centers for Disease Control and Prevention Multisystem Inflammatory Syndrome in Children Investigation Team* Abstract BACKGROUND A multisystem inflammatory syndrome in children (MIS-C) is associated with coronavirus disease 2019. The New York State Department of Health (NYSDOH) established active, statewide surveillance to describe hospitalized patients with the syndrome. METHODS Hospitals in New York State reported cases of Kawasaki’s disease, toxic shock syndrome, myocarditis, and potential MIS-C in hospitalized patients younger than 21 years of age and sent medical records to the NYSDOH. We carried out descriptive analyses that summarized the clinical presentation, complications, and outcomes of patients who met the NYSDOH case definition for MIS-C between March 1 and May 10, 2020.
  • 《JAMA,6月8日,Multisystem Inflammatory Syndrome Related to COVID-19 in Previously Healthy Children and Adolescents in New York City》

    • 来源专题:COVID-19科研动态监测
    • 编译者:xuwenwhlib
    • 发布时间:2020-06-09
    • Multisystem Inflammatory Syndrome Related to COVID-19 in Previously Healthy Children and Adolescents in New York City Eva W. Cheung, MD1; Philip Zachariah, MD, MS1; Mark Gorelik, MD1; et alAlexis Boneparth, MD1; Steven G. Kernie, MD1; Jordan S. Orange, MD, PhD1; Joshua D. Milner, MD1 Author Affiliations Article Information JAMA. Published online June 8, 2020. doi:10.1001/jama.2020.10374 Patients were included if they (1) were 21 years or younger; (2) were hospitalized at Columbia University Irving Medical Center/NewYork-Presbyterian Morgan Stanley Children’s Hospital in New York City between April 18 and May 5, 2020; (3) presented with a clinical syndrome characterized by prolonged fever, systemic inflammation, shock, end-organ dysfunction, or symptoms reminiscent of KD or TSS; and (4) had evidence of recent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. SARS-CoV-2 infection was determined by reverse transcriptase–polymerase chain reaction (RT-PCR) of nasopharyngeal swabs or positive serology. Serology testing was done using a New York State Department of Health–approved combined assay for IgM and IgG antibodies against SARS-CoV-2 spike trimer or nucleocapsid protein (96% specificity, 93% sensitivity). Admission testing included hematologic parameters, chemistries, co-infections, and inflammatory markers along with assessments of cardiac function (electrocardiograms, transthoracic echocardiograms). The Columbia University ethics committee approved the study with a waiver of informed consent.